Literature DB >> 3995722

Specific IgG subclass antibodies, IgE and IgG S-TS antibodies to wheat gluten fraction B in patients with coeliac disease.

P M Rawcliffe, D P Jewell, J A Faux.   

Abstract

Antibodies were measured in the sera of fifteen patients with untreated coeliac disease and twenty-eight patients with inflammatory bowel disease. Increased levels of specific IgG, IgG1, IgG2, and IgG4 antibody to wheat gluten fraction B, measured by an enzyme-linked immunosorbent assay, were shown in the coeliac disease group, but not in the inflammatory bowel disease group. No specific IgE antibody to fraction B was detected but 33% of the patients with coeliac disease had specific short-term sensitizing (anaphylactic) IgG antibody activity (IgG S-TS) to fraction B. There was no correlation between the IgG2 or IgG4 specific antibody and the presence of IgG S-TS activity.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3995722     DOI: 10.1111/j.1365-2222.1985.tb02268.x

Source DB:  PubMed          Journal:  Clin Allergy        ISSN: 0009-9090


  4 in total

1.  Serum IgG subclass antibodies to a variety of food antigens in patients with coeliac disease.

Authors:  M Hvatum; H Scott; P Brandtzaeg
Journal:  Gut       Date:  1992-05       Impact factor: 23.059

2.  Raised number of jejunal IgG2-producing cells in untreated adult coeliac disease compared with food allergy.

Authors:  T O Rognum; K Kett; O Fausa; U Bengtsson; A Kilander; H Scott; P I Gaarder; P Brandtzaeg
Journal:  Gut       Date:  1989-11       Impact factor: 23.059

3.  Serum IgG subclass antibodies to gliadin and other dietary antigens in children with coeliac disease.

Authors:  S Husby; N Foged; V A Oxelius; S E Svehag
Journal:  Clin Exp Immunol       Date:  1986-06       Impact factor: 4.330

4.  IgG, IgA and IgE gliadin antibody determinations as screening test for untreated coeliac disease in children, a multicentre study.

Authors:  A Bürgin-Wolff; R Berger; H Gaze; H Huber; M J Lentze; D Nusslé
Journal:  Eur J Pediatr       Date:  1989-04       Impact factor: 3.183

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.